After Novo Nordisk breached not one, not two, but seven clauses of the code that regulates U.K. drugmakers, its U.K. general manager is stepping down as president of the industry's national ...

Processing times for complaints against drug companies suspected of having breached their industry code of practice have more than tripled in a nearly two-decade period, an investigation by The BMJ ...

Novo Nordisk A/S (NYSE:NVO), the maker of the popular obesity drug Ozempic, has been reprimanded by the U.K.’s Prescription Medicines Code of Practice Authority (PMCPA) for failing to disclose fees ...

A U.K. pharma trade group suspended Novo Nordisk’s membership for two years after marketing efforts for its obesity drug were deemed a breach of the group’s standards. ABPI said it took the action ...

Processing times for complaints against drug companies suspected of having breached their industry code of practice have more than tripled in a nearly two-decade period, an investigation by The BMJ ...

LONDON, March 16 (Reuters) - The Association of the British Pharmaceutical Industry (ABPI), on Thursday said it has suspended Danish drugmaker Novo Nordisk for two years over "serious breaches".

A British Medical Journal (BMJ) investigation featuring data analysis from Dr. Piotr Ozieranski at the University of Bath and Dr. Shai Mulinari from Lund University, Sweden reveals processing times ...